|
Novartis receives European Commission approval for self-administration of Xolair® across all indications
|
13 December 2018 |
|
Alcon to highlight its vision, strategy and benefits as a standalone company to investors and analysts in New York and London
|
27 November 2018 |
|
Novartis rises to second place in 2018 Access to Medicine Index
|
21 November 2018 |
|
Novartis R&D update highlights industry leading development pipeline including potential blockbusters and advanced therapy platforms
|
05 November 2018 |
|
Novartis announces clinical collaboration with Pfizer to advance the treatment of NASH
|
29 October 2018 |
|
Alcon to develop SMART Suite digital health platform for cataract surgery
|
23 October 2018 |
|
Novartis 5-year data in psoriatic arthritis and ankylosing spondylitis reinforces Cosentyx® leadership in spondyloarthritis
|
16 October 2018 |
|
Sandoz announces global resolution of biosimilar adalimumab patent disputes, securing patient access
|
12 October 2018 |
|
Sandoz Healthcare Access Challenge #SandozHACk returns, seeking digital solutions to local healthcare access challenges
|
05 October 2018 |
|
Novartis licenses three novel anti-infective programs to Boston Pharmaceuticals
|
03 October 2018 |